PharmaDeals

2008-10-06
Eli Lilly has become the proud owner of ImClone, successfully outbidding Bristol-Myers Squibb (BMS) and paying nearly US$2 B more than BMS’ original offer in the process. ImClone fitted neatly into both companies’ strategies, though the size of this acquisition shows that Eli Lilly was the more eager out of the two. ImClone does, however, come with some strings attached.

2008-10-03
Genentech and Roche have entered into a new deal this month, although not the anticipated acquisition of the biotech by the Swiss giant. Instead the companies have formed a collaboration with GlycArt for the development of its antibody for the potential treatment of CD20-positive B-cell malignancies.

2008-09-30
Merck continues to look at countries with emerging markets and promising drug discovery capabilities in its bid to find good drug candidates to populate its pipeline. Its latest agreement with Chennai, India-based Orchid Chemicals and Pharmaceuticals is for the discovery and development of anti-infectives.